Meeder Asset Management Inc. Lowers Stock Holdings in Johnson & Johnson $JNJ

Meeder Asset Management Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 18.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 117,192 shares of the company's stock after selling 26,888 shares during the quarter. Johnson & Johnson makes up approximately 1.5% of Meeder Asset Management Inc.'s holdings, making the stock its 14th biggest holding. Meeder Asset Management Inc.'s holdings in Johnson & Johnson were worth $29,763,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of JNJ. Blueline Advisors LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at $25,000. Cresta Advisors Ltd. purchased a new stake in Johnson & Johnson in the fourth quarter worth about $26,000. Bay Harbor Wealth Management LLC grew its holdings in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock worth $31,000 after acquiring an additional 49 shares in the last quarter. Matrix Trust Co increased its position in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after purchasing an additional 54 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Johnson & Johnson by 946.7% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock valued at $32,000 after purchasing an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm's stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 63,972 shares of company stock valued at $16,245,605. 0.16% of the stock is currently owned by corporate insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved J&J’s oral psoriasis pill, Icotyde, expanding the company’s immunology portfolio and giving it a simpler treatment option to compete with rival products from Bristol Myers Squibb and AbbVie. The pill could also broaden J&J’s presence in China, although it may compete with the company’s established injectable Tremfya franchise. China approves J&J's oral psoriasis pill
• Positive Sentiment: The FDA expanded approval of Imaavy for warm autoimmune hemolytic anemia in patients 12 and older who are receiving or have previously received steroids. As the first approved treatment for this rare, potentially life-threatening disorder, Imaavy addresses an unmet need and could support J&J’s rare-disease growth strategy. Imaavy expands into rare blood disorder
• Positive Sentiment: Recent analysis points to a favorable shift in J&J’s product mix, with newer products increasingly offsetting pressure from the STELARA patent loss. This supports the view that growth in the broader Innovative Medicine portfolio may be more important than the shrinking contribution from STELARA. Did a product swap fuel JNJ stock's surge?
• Positive Sentiment: Investors continue to view JNJ as a defensive dividend holding, supported by its balance sheet, diversified healthcare operations and ability to generate dependable returns through economic cycles. Johnson & Johnson is a top dividend stock

Johnson & Johnson Trading Up 0.1%

NYSE JNJ opened at $268.30 on Monday. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $276.47. The company has a 50 day moving average price of $258.88 and a 200 day moving average price of $243.98. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a market cap of $646.58 billion, a PE ratio of 31.09, a price-to-earnings-growth ratio of 2.56 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same period last year, the firm earned $2.77 earnings per share. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is presently 62.11%.

Analyst Ratings Changes

A number of research firms have recently issued reports on JNJ. Royal Bank Of Canada increased their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. HSBC set a $290.00 target price on Johnson & Johnson and gave the stock a "buy" rating in a report on Monday, July 6th. Scotiabank reiterated an "outperform" rating and issued a $305.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $268.22.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source